// App-Quantinova.ai

262 : Health-related quality of life (HRQoL) in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) treated with nivolumab (N) plus chemotherapy (CT) or nivo plus ipilimumab (I) versus chemo: Results from CheckMate 648.

Researchers

Presenter

  • John A. Bridgewater

Principal Investigators

  • Ian Chau

  • Joseph Gricar

  • Steven I. Blum

  • Fiona Taylor

  • Rachael Lawrance

  • Brad Padilla

  • Christine Yip

  • Lucjan Wyrwicz

Medical Centers

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Adelphi Values, Boston, MA

  • Adelphi Values, Bollington, United Kingdom

  • Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

Locations

  • United Kingdom

  • United States

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal squamous carcinoma cell

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03143153

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved